1. Legal Issues in Compassionate Use Drug Access

“Compassionate use” or Expanded Access allows patients with serious or terminal illnesses to access investigational drugs outside clinical trials when no alternatives exist. Legally, this creates several complex issues:

A. No Fundamental Right to Experimental Drugs

A central legal issue is whether patients have a constitutional right to access unapproved drugs.

• Courts consistently hold: NO such right exists
• FDA regulation under the Food, Drug, and Cosmetic Act (FDCA) governs access

👉 Key principle:
Drug access is a regulated privilege, not a constitutional entitlement

B. FDA’s Regulatory Authority vs Patient Autonomy

There is constant tension between:

• Patient autonomy (right to choose life-saving treatment)
• FDA authority (protect public safety and ensure efficacy)

FDA requires:

• IND application approval
• IRB review
• Risk–benefit justification
• No interference with clinical trials

C. Safety vs Urgency Conflict

Ethical-legal conflict:

• Terminal patients argue: “risk is worth it”
• FDA argues: “unknown risks may be fatal”

Courts consistently side with:

Population safety and evidence-based medicine over individual urgency

D. Access Inequality

Legal concern:

• Wealthy patients or well-connected hospitals access drugs more easily
• Others cannot

But courts have ruled:

• Inequality alone does not invalidate FDA system

E. Manufacturer Liability and Control

Drug companies may refuse expanded access due to:

• Liability risks
• Drug shortage concerns
• Trial disruption

Legal issue:

• Can companies be forced to provide drugs?
  👉 Courts say NO

F. Role of IRB and Informed Consent

Even in compassionate use:

• Institutional Review Board (IRB) approval is mandatory
• Informed consent required

But legal question:

• Is consent enough to override safety regulation?
  👉 Courts say NO

2. Major Case Laws on Compassionate Use Drug Access

CASE 1: United States v. Rutherford (1979)

Facts:

Terminal cancer patients sought access to Laetrile, an unapproved drug derived from apricot pits. They argued that since they were terminally ill, FDA restrictions should not apply.

Legal Issue:

Do terminally ill patients have a legal right to access unapproved drugs?

Judgment:

U.S. Supreme Court held:

• FDCA applies even to terminally ill patients
• No exemption exists for “last-chance” treatments

Reasoning:

• Congress intended strict drug regulation
• Safety standards apply uniformly
• “Desperation does not justify bypassing science”

Legal Principle:

👉 Terminal illness does not create an exception to FDA regulation

CASE 2: Abigail Alliance v. Von Eschenbach (2007)

Facts:

Patient advocacy group sought access to Phase I investigational drugs for terminal patients who had no alternatives.

Legal Issue:

Is there a constitutional “right to try” experimental drugs?

Judgment (en banc D.C. Circuit):

• No fundamental constitutional right exists
• FDA restrictions pass rational basis review

Court Reasoning:

• Drug safety must be scientifically validated
• Early-phase drugs may have unknown toxicity
• Allowing access could destroy clinical trial integrity

Key Statement:

👉 “No constitutional right to investigational drugs exists”

Legal Principle:

• Expanded access is regulatory discretion, not constitutional right

CASE 3: Abigail Alliance v. FDA (Panel Decision 2006 – later overturned)

Facts:

A lower appellate panel initially supported limited access to drugs after Phase I trials.

Legal Issue:

Whether terminal patients with no options have liberty interest in access.

Judgment (initial panel):

• Suggested possible protected liberty interest under Due Process Clause

Outcome:

• Vacated by en banc court (Case 2)

Legal Importance:

• Shows judicial conflict before final rejection of right-to-try claims

CASE 4: Washington Legal Foundation v. Henney (1999)

Facts:

Challenge against FDA restrictions on communication about investigational drugs and expanded access.

Legal Issue:

Does FDA restriction violate First Amendment (free speech) rights of physicians and companies?

Judgment:

• Court limited FDA control over speech but upheld drug regulation authority

Key Holding:

• FDA can regulate distribution of investigational drugs
• But cannot overly restrict truthful scientific communication

Legal Principle:

👉 Speech rights exist, but drug distribution remains regulated

CASE 5: Mitchell v. Clayton (1993)

Facts:

Patients argued they had a right to receive specific medical treatment not approved by government systems.

Legal Issue:

Do patients have constitutional right to specific medical treatment?

Judgment:

• No constitutional right to specific treatment choices

Reasoning:

• Government may restrict unsafe or unproven therapies
• Medical regulation is valid state interest

Legal Principle:

👉 No right to choose unapproved treatment over regulatory restrictions

CASE 6: New York State Ophthalmological Society v. Bowen (1988)

Facts:

Doctors challenged federal restrictions on medical treatment choices.

Legal Issue:

Whether patient-physician decision-making is constitutionally protected from regulation.

Judgment:

• Government may regulate medical practice
• Patient autonomy is not absolute

Legal Principle:

👉 Medical choice is not free from government control

CASE 7: Grimes v. Kennedy Krieger Institute (2001)

Facts:

Children were involved in risky lead exposure research without adequate protections.

Legal Issue:

Whether children in research can be exposed to non-therapeutic risk.

Judgment:

• Court emphasized heightened protection for children in medical research

Importance for compassionate use:

• Strengthens IRB and ethical scrutiny in pediatric expanded access cases

Legal Principle:

👉 Children require enhanced protection in experimental medical contexts

3. Combined Legal Doctrine from These Cases

Across all case law, courts consistently establish:

1. No constitutional right to investigational drugs

(Rutherford, Abigail Alliance)

2. FDA has broad regulatory authority

(FDCA framework upheld repeatedly)

3. Compassionate use is discretionary, not mandatory

(FDA decides access)

4. Safety outweighs individual desperation

(All major cases)

5. Pediatric cases require higher ethical scrutiny

(Grimes principle extended)

4. Final Legal Understanding

Compassionate use drug access sits at the intersection of:

• Constitutional law (no fundamental right)
• Administrative law (FDA authority)
• Medical ethics (benefit vs harm)
• Human rights arguments (not legally enforceable in U.S.)

👉 Final doctrine:

“Access to investigational drugs is a regulated exception, not a legal right—even in life-threatening conditions.”